<DOC>
	<DOCNO>NCT00075257</DOCNO>
	<brief_summary>Primary Objective : To compare efficacy safety DVS-233 SR versus placebo treatment reduce relapse rate depressive symptom subject major depressive disorder ( MDD ) , compare percentage relapse term time relapse DVS-233 SR placebo treatment group use survival analysis . Secondary Objective : To assess response subject DVS-233 SR versus placebo clinical global evaluation , functionality , general well-being , pain , absence symptom ( Hamilton Psychiatric Rating Scale Depression , 17-item [ HAM-D17 ] &lt; 7 ) .</brief_summary>
	<brief_title>Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Inclusion criterion openlabel phase : Outpatients Men woman 18 75 year age , inclusive . Sexually active woman participate study must use medically acceptable form contraception ( Medically acceptable form contraception include oral contraceptive , injectable implantable method , intrauterine device , properly use barrier contraception ) Subjects must primary diagnosis MDD base criterion Diagnostic Statistical Manual Mental Disorders , 4th edition ( DSMIV ) , single recurrent episode , without psychotic feature ( If allowable psychiatric diagnosis present , MDD must predominant psychiatric disorder present . ) Treatment DVS233 SR time past Treatment venlafaxine ( immediate release [ IR ] ER ) within 90 day study day 1 Known hypersensitivity venlafaxine ( IR ER )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>